Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Fosun Buys 5% Stake in Tongjitang Chinese Medicines

publication date: Oct 21, 2008

Fosun Enterprises Ltd., a subsidiary of Fosun Pharmaceuticals, bought 1.8 million ADSs of Tongjitang Chinese Medicines (NYSE: TCM) on the open market, paying $7.4 million, representing an average price of $4.09 per share. Tongjitang was selling for about $4 per share during July and August, but since then has fallen further. After the purchase, Fosun holds about 5.37% of the outstanding stock of Tongjitang. More details...

Stock Symbols: (SHEX: 600196) (NYSE: TCM)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital